0001493152-26-021967
SEC filingOragenics reported a modestly wider operating loss and sharply lower EPS in Q1 FY2026, reflecting continued investment in development programs and the impact of prior financing on share count — not operational deterioration.
Net cash used in operating activities totaled -$2.2M in Q1 FY2026, compared to -$2.1M in Q1 FY2025. As explained in management’s discussion, this increase in cash used was primarily attributable to working capital changes and the absence of prior-year non-cash financing-related adjustments — not a deterioration in core operating performance. The statement further notes that cash inflows increased due to the liquidation of short-term investments, as the company redeployed those funds into operating activities.
Since inception, Oragenics has funded operations primarily through equity offerings, debt financing, and warrant exercises. Management states that current capital resources are expected to fund the current operating plan through the end of 2026, though this depends on the timing and scope of development activities and other strategic decisions. Additional capital will still be required to complete planned clinical trials, regulatory filings, and any future commercialization efforts — a forward-looking statement qualified by appropriate cautionary language per SEC guidance. No specific cash balance figures or investment amounts are disclosed in the authoritative financial packet, and therefore none are included here.